Neurocrine Biosciences Inc (NBIX) Files 10-K for the Fiscal Year Ended on December 31, 2019

Author's Avatar
Feb 07, 2020
Article's Main Image

Neurocrine Biosciences Inc (NBIX, Financial)(30-Year Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2019. Neurocrine Biosciences Inc engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. Neurocrine Biosciences Inc has a market cap of $9.5 billion; its shares were traded at around $103.15 with a P/E ratio of 312.58 and P/S ratio of 14.44. GuruFocus has detected 1 severe warning sign with Neurocrine Biosciences Inc. .

For the last quarter Neurocrine Biosciences Inc reported a revenue of $244.1 million, compared with the revenue of $131.5 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $788.1 million, an increase of 74.7% from last year. For the complete 30-year financial data, please go here.. For the last five years Neurocrine Biosciences Inc had an average revenue decline of 0% a year.

The reported diluted earnings per share was 39 cents for the year, compared with the loss per share of $1.05 in the previous year. The Neurocrine Biosciences Inc had an operating margin of 9.17%, compared with the operating margin of 8.18% a year before. The 10-year historical median operating margin of Neurocrine Biosciences Inc is -81.27%. The profitability rank of the company is 2 (out of 10).

At the current stock price of $103.15, Neurocrine Biosciences Inc is traded at 57.8% discount to its historical median P/S valuation band of $244.65. The P/S ratio of the stock is 14.44, while the historical median P/S ratio is 34.25. The stock gained 21.92% during the past 12 months.

For the complete 20-year historical financial data of NBIX, click here.